Stallergenes announces the approval in Japan of STG320, the first sublingual immunotherapy tablet for the treatment of house dust mite allergy

Stallergenes, a global healthcare company specialised in the diagnosis and treatment of allergies through allergy immunotherapy, announced today that its partner, Shionogi & Co., Ltd has received the approval of STG320 from the Japanese health authorities.

STG320 is the first immunotherapy tablet registered in Japan for the treatment of house dust mite induced allergic rhinitis.

STG320 is the first house dust mite immunotherapy tablet ever to obtain a Marketing Authorization in the world

“This approval marks a milestone for Stallergenes and its STG320 clinical development programme, as it is the first regulatory approval received worldwide for a house dust mite allergy immunotherapy tablet. It clearly shows that heath authorities recognize the quality and therapeutic value of the tablet developed by Stallergenes”, stated Christian Chavy, Chief Executive Officer of Stallergenes. “While market access conditions for STG320 are still under discussion, the approval of STG320 is further proof of the successful long-term collaboration between Stallergenes and Shionogi & Co., Ltd.”

Allergic rhinitis affects 25% of Japan’s population and asthma 6.7 %. House dust mites and Japanese cedar pollen are the two main causes of respiratory allergies in Japan. Since September 2010, Shionogi & Co., Ltd has been the exclusive partner of Stallergenes for the clinical development, registration, marketing and sales of sublingual house dust mite immunotherapy tablets and sublingual Japanese cedar pollen immunotherapy tablets. The approval of STG320 triggers the payment by Shionogi & Co., Ltd of €10 million to Stallergenes.

Stallergenes will also receive compensation on sales of STG320 in Japan.

To find out more about Stallergenes, please visit www.stallergenes.com.